Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves cross-ancestry prediction

Thomas J Hoffmann,Rebecca E Graff,Ravi K Madduri,Alex A Rodriguez,Clint L Cario,Karen Feng,Yu Jiang,Anqi Wang,Robert J Klein,Brandon L Pierce,Scott Eggener,Lin Tong,William Blot,Jirong Long,Louisa B Goss,Burcu F Darst,Timothy Rebbeck,Joseph Lachance,Caroline Andrews,Akindele O Adebiyi,Ben Adusei,Oseremen I Aisuodionoe-Shadrach,Pedro W Fernandez,Mohamed Jalloh,Rohini Janivara,Wenlong C Chen,James E Mensah,Ilir Agalliu,Sonja I Berndt,John P Shelley,Kerry Schaffer,Mitchell J Machiela,Neal D Freedman,Wen-Yi Huang,Shengchao A Li,Phyllis J Goodman,Cathee Till,Ian Thompson,Hans Lilja,Dilrini K Ranatunga,Joseph Presti,Stephen K Van Den Eeden,Stephen J Chanock,Jonathan D Mosley,David V Conti,Christopher A Haiman,Amy C Justice,Linda Kachuri,John S Witte

DOI: https://doi.org/10.1101/2023.10.27.23297676

2024-08-20

Abstract:We conducted a multi-ancestry genome-wide association study of prostate-specific antigen (PSA) levels in 296,754 men (211,342 European ancestry; 58,236 African ancestry; 23,546 Hispanic/Latino; 3,630 Asian ancestry; 96.5% of participants were from the Million Veteran Program). We identified 318 independent genome-wide significant (p≤5e-8) variants, 184 of which were novel. Most demonstrated evidence of replication in an independent cohort (n=95,768). Meta-analyzing discovery and replication (n=392,522) identified 447 variants, of which a further 111 were novel. Out-of-sample variance in PSA explained by our genome-wide polygenic risk scores ranged from 11.6%-16.6% in European ancestry, 5.5%-9.5% in African ancestry, 13.5%-18.2% in Hispanic/Latino, and 8.6%-15.3% in Asian ancestry, and decreased with increasing age. Mid-life genetically-adjusted PSA levels were more strongly associated with overall and aggressive prostate cancer than unadjusted PSA. Our study highlights how including proportionally more participants from underrepresented populations improves genetic prediction of PSA levels, offering potential to personalize prostate cancer screening.